Navigation Links
For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders' Opinions Indicate that AbbVie/Eisai's Humira Has the Best Clinical Profile Among Key Marketed Therapies
Date:6/3/2013

BURLINGTON, Mass., June 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that based on clinical data and the opinions of interviewed thought leaders, AbbVie/Eisai's Humira has the strongest clinical profile among key marketed products that treat psoriatic arthritis (PsA). None of the PsA therapies in development show advantages in efficacy over Humira, although UCB/Astellas's Cimzia has a clinical profile that is not differentiated from Humira based on thought leader opinion and clinical trial data.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

According to the DecisionBase 2013 report entitled Opportunity Remains for Novel Therapies That Address Rheumatologists' and Payers' Shared Views on Unmet Need in the TNF-Alpha-Inhibitor-Dominated PsA Market, while some other therapies in development hold promise, they have efficacy, safety and tolerability, and/or delivery disadvantages compared with Humira and Cimzia.

"The TNF-alpha inhibitors have set a high clinical standard that is challenging for emerging therapies to surpass," said Decision Resources Senior Analyst Bingnan Kang , Ph.D. "However, unmet needs exist for improvements in various efficacy, safety and tolerability, and delivery attributes. The PsA pipeline contains several agents with novel mechanisms of action that have the potential to fulfill some of these unmet needs."

The report also finds that physicians in the U.S. and Europe and managed care organization (MCO) pharmacy directors in the U.S. identify the need for new therapies with greater ability to halt progression of structural damage as a key unmet need. In addition, surveyed U.S. MCO pharmacy directors are particularly receptive to new PsA therapies that offer improved effect on signs and symptoms of arthritis over currently available therapies. Improvement of signs and symptoms and inhibition of progression of structural damage are two key treatment goals in the management of PsA.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
2. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
3. Forum Tackles the Rising Costs, Challenges and Diminished Outcomes Associated with Treating Obese Patients for Orthopaedic Conditions
4. Treating Poison Ivy Is A Snap! New Cortizone 10 Poison Ivy Relief Pads Launch Just In Time For Summer
5. Elektas Advanced Versa HD System to Begin Treating Cancer Patients at New Swiss Radiotherapy Clinic
6. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
7. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
8. Varian Medical Systems to Showcase Advanced Technologies for Treating Cancer with Image-Guided Radiotherapy and Radiosurgery at JASTRO Meeting in Tokyo, Japan
9. The Nairobi Hospital in Kenya Commences Treating Cancer with Advanced Radiotherapy Delivery Using Varian Equipment and Software
10. The Growing Cost of Aging: Express Scripts Study Shows Medication Use for Normal Aging Conditions Overtakes Costs of Treating Most Chronic Diseases
11. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2019)... United Kingdom (PRWEB) , ... June 15, 2019 ... ... http://www.lycote.com , has just published results of a clinical study on its new ... the company used different nutraceutical capsule and chocolate formulations, which were based on ...
(Date:6/14/2019)... , ... June 14, 2019 ... ... SIMPLY, a forecasting and analytics platform that helps Life Sciences Manufacturers accurately ... problems for Life Sciences business leaders: accurate, automated forecasting of rebates and ...
(Date:6/13/2019)... ... 2019 , ... Alliance Cost Containment, LLC (ACC) secured $5.8M in ... The $5.8M in savings is in addition to $17.6M saved over the course of ... acquisition in Q4 2019, the client increased their Fortune 500 status in the healthcare ...
Breaking Medicine Technology:
(Date:6/18/2019)... SEATTLE (PRWEB) , ... June 18, 2019 , ... ... company developing non-invasive treatments for cancers and other serious diseases, announced it has ... the EMulate Therapeutics application for Humanitarian Device Exemption (HDE) for the Hælo Pediatric ...
(Date:6/18/2019)... ... June 18, 2019 , ... Intalere, ... announced Steve Einig has joined the organization in the newly created role of ... around market engagement, marketing, strategic events and brand management. , “Steve brings a ...
(Date:6/16/2019)... ... June 16, 2019 , ... ... Holdings executives focusing on scientific research for the advancement of medical marijuana-based pharmaceuticals in ... your local listings for more information. , With two investigational new drug applications ...
(Date:6/13/2019)... ... ... Endometriosis is a painful, inflammatory disease that occurs when tissue grows outside of the uterus. ... Heavy bleeding , Irregular menstruation , Severe cramps , ... latest and newest treatment protocols in dealing with the symptoms of endometriosis. In the past, ...
(Date:6/13/2019)... (PRWEB) , ... June 13, 2019 , ... In Partnership ... free dental services for low-income, underinsured individuals at its Mesquite, TX office on July ... x-rays, fillings, cleanings and extractions . For more information, please visit ...
Breaking Medicine News(10 mins):